MOUNJARO® 7.5mg KwikPen®, 1 Stk.

Mounjaro® 7.5mg is a once-weekly injectable medication containing tirzepatide, a novel dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is prescribed for adults with type 2 diabetes mellitus whose condition is inadequately controlled by diet and exercise, and it is also approved for weight management in adults with obesity or overweight accompanied by related health conditions. Each single-dose prefilled pen delivers 7.5 mg of tirzepatide in 0.6 mL of solution (15 mg/mL concentration).

Tirzepatide lowers blood sugar by enhancing insulin secretion, improving insulin sensitivity, and reducing glucagon levels in a glucose-dependent manner. It also helps regulate appetite and energy balance, promoting sustainable weight reduction. Clinical studies have demonstrated an average HbA1c reduction of 2.1% and weight loss exceeding 8–10 kg in patients treated with the 7.5 mg dose compared to placebo or other glucose-lowering agents.

We have other products under the MOUNJARO® brand, like MOUNJARO® 5mg KwikPen®, 1 Stk.

Mounjaro 7.5mg is indicated for adults with type 2 diabetes mellitus as an adjunct to diet and physical activity to achieve improved glycaemic control and for weight management when clinically appropriate.

Therapeutic indications include:

• Monotherapy: For patients intolerant to metformin or in whom it is contraindicated.

• Combination therapy: Alongside metformin, SGLT2 inhibitors, sulphonylureas, or insulin.

• Weight management: For patients with BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² plus one or more obesity-related comorbidities such as hypertension, dyslipidaemia, prediabetes, or cardiovascular disease.

Contraindications:

• Hypersensitivity to tirzepatide or any excipient.

• Pregnancy or breastfeeding (should be discontinued at least 1 month before planned pregnancy).

• Severe gastrointestinal disorders, particularly gastroparesis.

• Caution is advised in patients with a history of pancreatitis or diabetic retinopathy requiring active treatment.

Side Effects:
Most adverse effects occur during the dose-escalation phase and are typically mild to moderate in intensity.

• Very common: Nausea, vomiting, diarrhoea, abdominal pain, constipation.

• Common: Decreased appetite, fatigue, dyspepsia, injection-site redness or itching.

• Uncommon/Rare: Hypoglycaemia (especially with insulin or sulphonylureas), acute pancreatitis, gallbladder disease, dizziness, hair loss, and allergic reactions such as urticaria or angioedema.
  In trials, gastrointestinal reactions were reported in up to 40% of patients but declined significantly after dose stabilization

Each dose of Mounjaro 7.5mg contains tirzepatide, a synthetic peptide that combines GIP and GLP-1 receptor activation to improve insulin response, appetite regulation, and fat utilization.

Composition per 0.6 mL dose:

• Tirzepatide 7.5 mg (15 mg/mL).

• Excipients: Glycerol, disodium phosphate, sodium phosphate monohydrate, benzyl alcohol, and water for injection.

• Solution appearance: Clear and colorless to slightly yellow, free from particles.

• Concentration: 12.5 mg/mL in 2.4 mL pen, sufficient for 4 doses.

• Container: KwikPen® multi-dose disposable prefilled pen, single-patient use only.

• Needles: Not included—use KwikPen-compatible sterile needles.

• Label color: Distinctive orange for 7.5 mg strength.

• Shelf life: Up to 30 days after initial use.

The Mounjaro 7.5mg KwikPen® is intended for once-weekly subcutaneous administration. It delivers a consistent dose automatically and is suitable for self-administration following proper instruction.

Administration guidelines:

1. Inspect the pen: Verify dose, expiration date, and solution clarity.

2. Attach a new sterile needle before each injection; never reuse needles.

3. Prime the pen by turning the dose knob until two clicks are heard and pressing to release a small drop of medicine.

4. Select an injection site — abdomen, thigh, or upper arm — rotating sites each week.

5. Dial the dose until “1” appears in the window (representing 0.6 mL = 7.5 mg).

6. Inject subcutaneously, holding the dose knob pressed for 5 seconds until “0” appears in the window.

7. Dispose of the used needle in a sharps container and replace the pen cap.

Missed Dose Instructions:

• If ≤ 4 days late: inject as soon as remembered.

• If > 4 days late: skip and resume next scheduled dose.

• Ensure at least 3 days between doses.

Patients should continue dietary management and exercise as advised by their healthcare professional. The pen must not be shared to prevent cross-contamination.